Press Releases

2014

2013

12/13/13 AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer
11/07/13 AVEO Reports Third Quarter 2013 Financial Results
09/04/13 AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference
08/09/13 AVEO Oncology to Present at the Canaccord Genuity 33rd Annual Growth Conference
08/08/13 AVEO Reports Second Quarter 2013 Financial Results
06/10/13 AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma
06/04/13 AVEO Oncology Announces Strategic Restructuring
05/15/13 AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
05/02/13 AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
05/02/13 Trading of AVEO Common Stock Halted
04/29/13 AVEO Reports First Quarter 2013 Financial Results
03/06/13 AVEO Oncology to Present at the Barclays Global Healthcare Conference
02/27/13 AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
02/20/13 AVEO Oncology to Present at the 2013 RBC Capital Markets’ Healthcare Conference
02/13/13 AVEO Reports 2012 Financial Results and Highlights Recent Accomplishments
02/12/13 AVEO and Astellas Report Final Overall Survival Results from TIVO-1
01/31/13 AVEO Oncology Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Conference Call
01/29/13 AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium
01/24/13 AVEO Announces Closing of Public Offering
01/22/13 AVEO Announces Exercise of Over-Allotment Option for Recent Public Offering
01/17/13 AVEO Prices Public Offering of Common Stock
01/16/13 AVEO Announces Proposed Public Offering of Common Stock

2012

12/27/12 AVEO Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference
12/20/12 AVEO Oncology Appoints Robert Epstein, M.D., M.S. to its Board of Directors
12/3/12 AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer
11/28/12 AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
11/26/12 AVEO Oncology to Present at the Deutsche Bank 2012 dbAccess BioFEST Conference
11/06/12 AVEO Oncology to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10/30/12 AVEO Announces Strategic Restructuring and Provides Third Quarter Financial Results
10/23/12 AVEO Oncology Announces Timing for Third Quarter Financial Results, Webcast and Conference Call
10/01/12 AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer
10/01/12 AVEO Announces Detailed Results of Exploratory Phase 2 Study Evaluating Ficlatuzumab in First-Line Patients with Advanced Non-small Cell Lung Cancer; New Data Presented at ESMO
09/28/12 AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
09/20/12 New Clinical Data on AVEO Oncology’s Tivozanib and Ficlatuzumab to be Presented at the ESMO 2012 Congress
09/13/12 AVEO Oncology to Present at the UBS Annual Global Life Sciences Conference
09/03/12 AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference
08/09/12 AVEO Oncology to Present at the Canaccord Genuity 32nd Annual Growth Conference
08/02/12 AVEO Reports Second Quarter 2012 Financial Results
07/26/12 AVEO Oncology Announces Timing for Second Quarter Financial Results, Webcast and Conference Call
06/04/12 AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
05/30/12 AVEO Oncology to Host Conference Call and Webcast to Review Phase 3 TIVO-1 Data Presented at ASCO
05/29/12 AVEO Oncology to Present at the Jefferies 2012 Global Healthcare Conference
05/23/12 AVEO Initiates Phase 1 Study of AV-203, an ERBB3 Inhibitory Antibody, in Advanced Solid Tumors
05/16/12 AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
05/03/12 AVEO Reports First Quarter 2012 Financial Results and Recent Developments
05/02/12 AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer
04/30/12 AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences
04/26/12 AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter Financial Results, Webcast and Conference Call
04/12/12 AVEO Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology
03/27/12 Data on AVEO Pharmaceuticals’ Tivozanib and AV-203 to Be Presented at AACR Annual Meeting 2012
02/27/12 AVEO Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
02/14/12 AVEO Reports 2011 Financial Results and Highlights Fourth Quarter Progress
02/07/12 AVEO Pharmaceuticals, Inc. Announces Timing for Fourth Quarter and Year-End 2011 Financial Results, Webcast and Conference Call
02/02/12 AVEO Pharmaceuticals to Present at Several Upcoming Investment Conferences
01/03/12 AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial
01/02/12 AVEO Pharmaceuticals, Inc. Announces Webcast and Conference Call

2011

12/28/11 AVEO Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
12/22/11 AVEO Announces Patient Enrollment in Phase 2 Clinical Trial of Tivozanib in Combination with mFOLFOX6 in Patients with Advanced Colorectal Cancer
12/01/11 AVEO Pharmaceuticals and Boehringer Ingelheim Announce Manufacturing Agreement for Ficlatuzumab
11/03/11 AVEO to Present Tivozanib Clinical Data at Upcoming Oncology Medical Congresses
11/02/11 AVEO Pharmaceuticals Reports Third Quarter 2011 Financial Results
10/26/11 AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results, Webcast and Conference Call
08/31/11 AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences
08/02/11 AVEO Pharmaceuticals, Inc. to Present at the Canaccord Genuity 31st Annual Growth Conference
07/28/11 AVEO Reports Second Quarter 2011 Accomplishments and Financial Results
07/21/11 AVEO Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results, Webcast and Conference Call
06/21/11 AVEO Pharmaceuticals Announces Closing and Exercise of Over-Allotment Option for Recent Public Offering
06/15/11 AVEO Pharmaceuticals Prices Public Offering of Common Stock
06/14/11 AVEO Pharmaceuticals Announces Proposed Public Offering of Common Stock
06/02/11 AVEO’s Ficlatuzumab in Combination with Gefitinib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCO
06/02/11 Final Analysis from AVEO Pharmaceuticals’ Phase 2 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma Presented at ASCO
05/31/11 AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies
05/27/11 AVEO Pharmaceuticals, Inc. to Present at the Jefferies 2011 Global Healthcare Conference
05/18/11 Clinical Data Evaluating AVEO Pharmaceuticals’ Tivozanib and Ficlatuzumab to be Presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
04/28/11 AVEO Reports First Quarter 2011 Accomplishments and Financial Results
04/26/11 AVEO Pharmaceuticals, Inc. to Present at the Deutsche Bank Securities 36th Annual Health Care Conference
04/21/11 AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results, Webcast and Conference Call
04/12/11 AVEO Pharmaceuticals Appoints Henri A. Termeer to its Board of Directors
03/31/11 AVEO Pharmaceuticals, Inc. to Present at the Leerink Swann Cancer Roundtable Conference
03/28/11 Preclinical Data on AVEO Pharmaceuticals’ Tivozanib and Monoclonal Antibody Pipeline to be Presented at AACR 102nd Annual Meeting 2011
02/23/11 AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences
02/16/11 AVEO Reports 2010 Financial Results and Highlights Progress with Tivozanib and Ficlatuzumab
02/16/11 Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia
02/14/11 AVEO Pharmaceuticals’ Tivozanib Clinical Data Featured at the 2011 ASCO Genitourinary Cancers Symposium
02/10/11 AVEO Pharmaceuticals, Inc. Announces Timing for 2010 Financial Results, Webcast and Conference Call
02/03/11 AVEO Pharmaceuticals Receives USAN Name for Novel, Internally Discovered Anti-HGF/c-MET Pathway Antibody
02/01/11 AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib
01/21/11 AVEO Pharmaceuticals’ Tivozanib Clinical Data Featured at 2011 ASCO Gastrointestinal Cancers Symposium
01/04/11 AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference

For media inquiries, please contact: David Pitts of Argot Partners (212) 600-1902